Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients

ABSTRACT:

ORGANISM(S): Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Covid-19

PROVIDER: ST002087 | MetabolomicsWorkbench |

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling Metabolites and Lipoproteins in COMETA, an Italian Cohort of COVID-19 patients-part 2

Project description: Not available

| ST002404 | MetabolomicsWorkbench

Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients.

Project description: Not available

| S-EPMC9022834 | biostudies-literature

In-depth plasma proteome profiling of COVID-19 patients

Project description:Coronavirus disease 2019 (COVID-19) is an unprecedented global threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is a global health crisis. Recent reports have exposed an astonishing case fatality rate of 61.5% for critical cases, increasing sharply with age and for patients with underlying comorbidities. Mass spectrometry (MS)-based proteomics has the potential to become an ideal technology to be applied in this urgent situations, because it can quickly deliver substantial amounts of clinical and biological information from blood plasma or serum in an untargeted fashion. Furthermore, these MS-based proteomic workflows for biomarker discovery and profiling are well established. However, only two studies have presently applied proteomics to serum of COVID-19 patients with moderate proteome depth. Therefore, it is necessary to gain a more detailed understanding with in-depth proteome of plasma or serum to develop prognostic or predictive protein markers. In this study, we performed in-depth proteome profiling of undepleted plasma samples using BoxCar acquisition method from an exploratory cohort comprising ten COVID-19 patients to identify candidate biomarkers for disease severity evaluation.

2021-05-15 | PXD020354 | Pride

microRNA profiling in the plasma of hospitalized COVID-19 patients

Project description:Coronavirus disease 2019 (COVID-19) can be asymptomatic or lead to a wide spectrum of symptoms, ranging from mild upper respiratory system involvement to acute respiratory distress syndrome, multi-organ damage and death. In this study, we explored the potential of microRNAs (miRNA) in delineating patient condition and in predicting clinical outcome. Analysis of the circulating miRNA profile of COVID-19 patients, sampled at different hospitalization intervals after admission, allowed to identify miR-144-3p as a dynamically regulated miRNA in response to COVID-19.

2023-01-27 | GSE195898 | GEO

Nanostring plasma microRNA profiling in hospitalised patients with COVID-19

Project description:Circulating microRNAs (miRNAs) have been shown to be excellent disease diagnostic or prognostic biomarkers in a wide range of chronic and acute inflammatory and infectious diseases including viral respiratory infection. Crucially, circulating miRNA levels are thought to reflect the state of the diseased tissue. Despite their proven value as mechanism-based clinical stratification indicators, miRNAs have only started being explored in the context of COVID-19. here, we aimed to explore whether integrating miRNA with other clinical and biological measurements would reveal more accurate correlates of COVID-19 severity and outcome, and to identify severity-specific correlations of miRNAs with COVID-19-associated inflammatory mediators, clinical parameters, and otucome.

2021-12-09 | GSE189610 | GEO

Study of Immunological and Inflammatory gene response in Indian Cohort of Covid-19 Patients by NanoString Technology

Project description:The Nanostring nCounter gene expression assay was used to investigate the molecular signalling of host to Covid-19 infection, from Indian Cohort. The study revealed several biomarkers with strong predictive performance to differentiate Covid-19 infection from healthy controls and markers to differentiate between Covid-19 infection from other flu like symptoms.

2025-07-30 | GSE252594 | GEO

Proteomic analysis neutrophils from COVID-19 patients

Project description:To go further insight into the involvement of neutrophils in COVID-19 clinical expression, we performed a proteomic analysis of this blood cell type in COVID-19 patients and two non-infected SARS-CoV-2 control groups composed of healthy subjects and ARDS patients hospitalized in intensive care unit (ICU) respectively. All patients were from Guadeloupe and represent a homogeneous population. We have performed a quantitative proteomic study of neutrophiles from French hot spot COVID region, Guadeloupe, confirming the activation of type I IFN pathway and in some target of IFN as TAP proteins, specifically in COVID patients, but not in hospitalized ARDS non-COVID patients and described modification of the NET proteome potentially associated with ARDS.

2022-07-27 | PXD033293 | Pride

Metabolomic profiling of twenty metabolites from human tissues in six studies

Project description:Twenty metabolites across 6 studies, with 6 groups of experimental subjects

2008-06-21 | E-TABM-290 | biostudies-arrayexpress

Biomarker identification in hospitalised patients with COVID-19: a cohort study of acute infection and convalescence.

Project description:Pilot bottom-up depleted proteomic analysis of patients from the ManARTS COVID-19 cohort in early stages of the pandemic, for method development of high-throughput proteomics using small volumes of plasma and a 15-minute gradient. Demonstrates proof-of-concept for stratifying patients in an opportunistically collected cohort in a pandemic setting using available hospital data. Convalescent patients were used as an age and sex-matched comparator group against critically ill patients with a current infection.

2026-06-08 | PXD061500 | Pride

Effects of Dexamethasone in COVID-19 patients

Project description:Dexamethasone improves the survival of COVID-19 patients in need of supplemental oxygen therapy. Hospitalized COVID-19 patients eligible for dexamethasone therapy were recruited from the general care ward in several centers in Greece and the Netherlands and whole blood transcriptomic analysis was performed before and after starting dexamethasone treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy individuals and COVID-19 patients and stimulated with inactivated SARS-CoV-2 ex vivo in the presence or absence of dexamethasone and their transcriptome was assessed.

2023-07-26 | GSE227585 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data